Instituto Valenciano de Oncologia-ko ikertzaileekin lankidetzan egindako argitalpenak (5)

2023

  1. Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer

    Nature Communications, Vol. 14, Núm. 1

2020

  1. Targeted metabolomics analyses reveal specific metabolic alterations in high-grade prostate cancer patients

    Journal of Proteome Research, Vol. 19, Núm. 10, pp. 4082-4092

2019

  1. Metabolomics contributions to the discovery of prostate cancer biomarkers

    Metabolites, Vol. 9, Núm. 3

2017

  1. Erratum to: Non-invasive urinary metabolomic profiling discriminates prostate cancer from benign prostatic hyperplasia (Metabolomics (2017) 13:52, 10.1007/s11306-017-1194-y)

    Metabolomics

  2. Non-invasive urinary metabolomic profiling discriminates prostate cancer from benign prostatic hyperplasia

    Metabolomics, Vol. 13, Núm. 5